Intrust Bank NA Has $9.99 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Intrust Bank NA trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,941 shares of the company’s stock after selling 414 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of Intrust Bank NA’s investment portfolio, making the stock its 22nd biggest position. Intrust Bank NA’s holdings in Eli Lilly and Company were worth $9,990,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Hobbs Group Advisors LLC boosted its position in shares of Eli Lilly and Company by 5.0% in the fourth quarter. Hobbs Group Advisors LLC now owns 272 shares of the company’s stock valued at $210,000 after acquiring an additional 13 shares during the period. Biondo Investment Advisors LLC boosted its holdings in Eli Lilly and Company by 0.7% in the 4th quarter. Biondo Investment Advisors LLC now owns 17,941 shares of the company’s stock valued at $13,851,000 after purchasing an additional 117 shares during the period. Allstate Corp grew its position in shares of Eli Lilly and Company by 3,191.1% during the 4th quarter. Allstate Corp now owns 23,992 shares of the company’s stock worth $18,522,000 after purchasing an additional 23,263 shares in the last quarter. Maridea Wealth Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $252,000. Finally, Brown Brothers Harriman & Co. raised its position in shares of Eli Lilly and Company by 21.6% in the fourth quarter. Brown Brothers Harriman & Co. now owns 26,358 shares of the company’s stock valued at $20,348,000 after buying an additional 4,690 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.2 %

Shares of LLY opened at $820.30 on Friday. The stock’s 50-day moving average price is $844.31 and its two-hundred day moving average price is $836.82. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company has a market capitalization of $777.78 billion, a PE ratio of 70.05, a PEG ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LLY shares. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Friday, January 17th. Citigroup dropped their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.